Tweaking the pirfenidone molecule yields an evidently effective but less toxic antifibrotic drug, investigators say.

Among patients with pulmonary arterial hypertension treated with selexipag, the 10-year survival rate was 60%, according to ...

A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile.

Discover the causes, symptoms, and treatment of food allergies, and learn how to manage them safely with expert tips on ...

In a 2014 Nature paper, Ralston described this awkward process — trogocytosis, or “cell nibbling.” It was a revelation at the ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

Many agree that the original course of vaccination offered significant protection against serious illness in children. Data ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.